MyelinZ® Company Profile

Background

MyelinZ® is a neurotechnology company dedicated to revolutionizing brain health monitoring and rehabilitation. The company's mission is to empower over a billion individuals living with brain disorders, including the 2.8 million people affected by multiple sclerosis. By developing home-ready brain-machine interface (BCI) technology, MyelinZ aims to redefine how cognitive and physical health are monitored, trained, and rehabilitated. Additionally, the company's neurotechnology supports deep space missions, enhancing cognitive performance and aiding astronaut training and recovery.

Key Strategic Focus

MyelinZ focuses on developing advanced BCI technologies that facilitate real-time and remote monitoring of neurological diseases, with a particular emphasis on multiple sclerosis and Parkinson's disease. The company's products are designed to be scalable, addressing a wide range of brain disorders. By integrating neuroscience, artificial intelligence, bio-sensing, and neuroengineering, MyelinZ aims to create innovative solutions that transform brain health care.

Financials and Funding

As of June 2025, specific details regarding MyelinZ's funding history, total funds raised, and notable investors have not been publicly disclosed. The company continues to focus on advancing its technological platforms and expanding its market presence.

Pipeline Development

MyelinZ is actively developing its flagship product, BodyMirror, a BCI technology intended for research applications and personal use. While not classified as a medical device under EU Directive 93/42/EEC, BodyMirror is designed to assist in real-time and remote monitoring of neurological conditions. The company is also preparing for a significant multi-site clinical trial scheduled to commence in 2024, aiming to further validate and enhance its product offerings.

Technological Platform and Innovation

MyelinZ's technological platform integrates proprietary BCI technologies with advanced software solutions to monitor and rehabilitate brain health. The company's products are designed to be home-ready, enabling users to engage in cognitive and physical health training remotely. By leveraging machine learning algorithms and neuroengineering methodologies, MyelinZ sets itself apart in the neurotechnology industry.

Leadership Team

• Dr. Zied Tayeb: Founder and CEO of MyelinZ. Dr. Tayeb leads the company's strategic vision and oversees the development of its neurotechnology solutions.

• Samaher Garbaya: Co-Founder and COO of MyelinZ. Ms. Garbaya manages the company's operations and plays a pivotal role in its growth and development.

Leadership Changes

As of June 2025, there have been no significant changes or appointments within MyelinZ's leadership team.

Competitor Profile

Market Insights and Dynamics

The neurotechnology market is experiencing significant growth, driven by increasing demand for innovative solutions in brain health monitoring and rehabilitation. Advancements in BCI technologies and the integration of AI are key factors contributing to this expansion.

Competitor Analysis

While specific competitors of MyelinZ are not detailed in the available information, companies operating in the neurotechnology and BCI sectors are considered potential competitors. These companies focus on developing technologies for brain health monitoring, cognitive enhancement, and rehabilitation, utilizing various proprietary technologies and scientific methodologies.

Strategic Collaborations and Partnerships

As of June 2025, specific details regarding MyelinZ's collaborations, partnerships, or alliances have not been publicly disclosed. The company continues to focus on advancing its technological platforms and expanding its market presence.

Operational Insights

MyelinZ's strategic considerations involve maintaining a competitive position in the neurotechnology market by focusing on innovation, product development, and addressing the needs of individuals with neurological disorders. The company's emphasis on home-ready BCI technologies and support for deep space missions serve as distinct competitive advantages.

Strategic Opportunities and Future Directions

Looking ahead, MyelinZ aims to expand its product offerings, enter new markets, and establish strategic partnerships to enhance its technological capabilities. The upcoming multi-site clinical trial in 2024 represents a significant milestone in validating the efficacy of its products and strengthening its position in the neurotechnology industry.

Contact Information

• Website: myelinz.com

• Email Addresses:

• General Inquiries: info@myelinz.com

• BodyMirror Product Inquiries: bodymirror@myelinz.com

• Press Inquiries: press@myelinz.com

• Career Opportunities: careers@myelinz.com

• Investment Inquiries: investment@myelinz.com

• R-MMS Inquiries: r-mms@myelinz.com

• SpaceMirror Inquiries: myelinspace@myelinz.com

• Social Media:

• LinkedIn: linkedin.com/company/myelinz

• Twitter: twitter.com/myelinz

• Facebook: facebook.com/myelinz

• Instagram: instagram.com/myelinz

Please note that MyelinZ's products, including BodyMirror technology, are intended for research applications and personal use only. They are not classified as medical devices under EU Directive 93/42/EEC and are not designed or intended for the diagnosis or treatment of any disease.